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Abstract 
Background: Detection of tumor cells in the blood, or minimal deposits in distant organs as bone marrow, could be 
important to identify cancer patients at high risk of relapse or disease progression. Quantitative polymerase chain 
reaction (PCR) amplification of tissue or tumor selective mRNA is the most powerful tool for the detection of this 
circulating or occult metastatic cells. Our study aims to identify novel gastrointestinal cancer-specific markers for 
circulating tumor cell detection. Method: Phase I preclinical study was performed by means of computational tools 
for expression analysis. In silico data were used to identify and prioritize molecular markers highly expressed in 
gastrointestinal cancers but absent in hematopoietic-derived libraries. Selected genes were evaluated by means of 
qRT-PCR in gastrointestinal cancer and hematopoietic cell-lines, normal human bone marrows and bloods, tumor 
tissue, and blood from cancer patients. Results: Novel and known mRNA markers for circulating tumor cell detection 
in gastrointestinal cancer have been identified. Among all the genes assessed, PKP3, AGR2, S100A16, S100A6, 
LGALS4, and CLDN3 were selected and assays based on blood qRT-PCR were developed. Reliably qRT-PCR 
assays for the novel targets plakophilin 3 (PKP3) and anterior gradient-2 (AGR2) to identify blood-borne cells in 
cancer patients were developed. Conclusions: Novel and known gastrointestinal-specific mRNA markers for 
circulating tumor cells have been identified through in silico analysis and validated in clinical material. qRT-PCR 
assay targeted to PKP3 and AGR2 mRNAs might be helpful to detect circulating tumor cells in patients with 
gastrointestinal cancer. 
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1. Introduction 
Cancer of the gastrointestinal (GI) system encompasses a great proportion of tumor-related deaths in 
the world. Stage at the time of diagnostic and suitability for curative surgery remains the most important 
prognostic factors for digestive tract tumors. However, distant and loco-regional relapses frequently occur 
in spite of resection and adjuvant therapy. Colorectal cancer is the second leading cause of cancer deaths 
in the western countries. Most of these patients are diagnosed with localized disease, but their average 5-
year survival is 50–60% in European countries [1]. For patients with other common GI malignancies, the 
options for curative resections are limited and survival remains poor, especially for esophageal and gastric 
carcinomas and pancreatic cancer. 
 
Circulating tumor cells and occult metastasis (micrometastasis) are considered early stages in the 
progression of metastatic cascade in epithelial cancer. Detection of tumor cells in the blood or minimal 
deposits in distant organs as bone marrow could be important to identify patients at high risk of relapse or 
disease progression. 
 
PCR amplification of tissue or tumor-selective mRNA is the most powerful tool for detection of this 
circulating or occult metastatic cells. Cytokeratin 20, carcinoembryonic antigen (CEA), and epidermal 
growth factor receptor (EGFR) are among the most frequent mRNA markers used in different reverse-
transcriptase polymerase-chain reaction (RT-PCR) assays in GI-cancer patients [[2], [3]]. However, 
cancer genetic heterogeneity, down-regulation of mRNA marker in tumor cells, or low-level transcription 
of selected target in the hematopoietic compartment could compromise both sensitivity and specificity of 
molecular methods. 
 
Selection of novel gastrointestinal cancer-specific transcripts and development of multi-marker 
quantitative RT-PCR assays are clearly outstanding research questions [[4], [5]]. 
 
EGFR has been found to be overexpressed in a high proportion of gastrointestinal cancer and confers 
a poor prognosis [6]. Development of a quantitative assay to detect EGFR-expressing circulating tumor 
cells could be relevant for prognostic assessment, monitor response, or even thought select target therapy 
[7]. 
 
RT-PCR assays for different glycosyltransferases have been developed for tumor cells detection in 
blood for breast cancer and melanoma patients [8]. Beta-1,6-N-acetylglucosaminyltransferase V (GNT-V, 
MGAT5; Hs.200/Mm.161; EC 4.1.155) expression in colorectal cancer had been correlated with 
metastasis and poor prognosis [9]. Thus GNT-V could represent a suitable mRNA biomarker for 
circulating tumor cell detection in gastrointestinal cancer patients. 
 
The present study aims to identify novel GI cancer-specific markers for circulating tumor cells (CTC) 
detection. The development of mRNA-based tools for CTC biomarkers was done following the proposed 
guidelines of the Early Detection Research Network (EDRN) by the National Cancer Institute [10]. Phase 
I preclinical study was performed by means of computational tools for expression analysis. In order to 
validate the usefulness of this in silico approach to identify tumor cells markers, selected genes were 
evaluated in cell lines and clinical specimens. Finally, qRT-PCR assays for the novel targets plakophilin 3 
(PKP3) and anterior gradient-2 (AGR2) to identifiy blood-borne cells in cancer patients were developed. 
  
2. Materials and methods 
2.1. Digital differential display and computational tools 
Digital differential display (DDD) [11] is an in silico data-mining resource of the National Centre for 
Biotechnology Information (NCBI) for comparing sequence-based gene representation profiles. DDD is 
based on the UniGene concept and provides the genes that are represented at different levels in the 
selected cDNA libraries using statistical tests. DDD was used to identify molecular markers highly 
expressed in GI cancers but absent in blood and bone marrow-derived EST libraries. A set of cDNA 
libraries from blood and bone marrow (n = 13) was selected and it was compared with three pools of 
colon (n = 10), gastric (n = 13), and pancreatic (n = 5) carcinoma cDNA libraries. Each set was selected 
to include the broad heterogeneity of every tumor type and includes the minimum possible number of 
libraries generated from normalized or subtracted cDNAs. 
 
Tags with statistically significant (p < 0.05; Fisher's exact test) higher expression in GI cancer 
libraries were detected and each EST was identified by UniGene cluster. 
 
ESTs whose expression was 10 or more times higher in each set of cancer libraries in comparison with 
blood and bone marrow-derived EST libraries were selected. As a second filter step, we selected those 
tags with undetectable or low representation in hematopoietic control libraries, defined as an expression 
count equal or less than four in DDD output. 
 
Furthermore, the tissue distribution and tumor specificity of every gene selected were analyzed using 
representation profiles obtained with virtual northern blot [VN, Ref. [12]]. For each combination of tissue 
and pathologic status, VN shows a spot image representing the expression level of the selected gene and 
numeric columns. These represent the number of ESTs or SAGE tags corresponding to the gene divided 
by the total number of ESTs or SAGE tags in all libraries with the given tissue/histology. The statistical 
significance of the observed counts is measured using Bayesian analysis. Values (p) less or equal to 0.05 
were considered significant [13]. Virtual northern blots for EGFR [14] and GNT-V [15] were also 
obtained. Functional data about the different gene selected were extracted from Gene Ontology (GO) 
annotations accessed in the Cancer Gene Anatomy Project (CGAP) database [[12], [16]]. 
2.2. Cell lines 
As a surrogated model of gastrointestinal cancer, the following human tumor cell-lines were used: 
colorectal carcinoma Gp5d, LoVo, DLD1, LS513, HT29, OJC4, OJC5, OJC6; gastric adenocarcinoma 
OE19, and pancreatic carcinoma OJC1. In addition, hematopoietic cell lines Jurkat, KG1, and K562 were 
analyzed. 
 
The cell-lines OJC1, OJC4, OJC5, and OJC6 were developed in our laboratory from clinical 
specimens and they have been fully characterized [17]. All the cell lines were maintained in DMEM 
(Dulbecco's modified Eagle's medium-high glucose) and MegaCell™ RPMI-1640 mediums (both 
provided by Sigma–Aldrich) supplemented with 10% fetal calf serum inactivated, 1% penicillin, 1% 
streptomycin, and 1% amphotericin at 37 °C in 5% CO2. Cells from adherent cultures were recovered 
with 1% trypsin–1% EDTA cell dissociating reagent. Cell pellets from suspension cultures were obtained. 
  
2.3. Clinical tissue specimens and blood preparation 
Formalin-fixed and paraffin-embedded tissue (FFPE) from colon cancer specimens (n = 16) were 
obtained from the Pathology Department of the Juan Canalejo University Hospital. Array tissue 
apparatus, provided by Durviz, was used to obtain tissue cores with 2 mm diameter, selecting an area 
enriched for tumor tissue. These FFPE cores were used for specific mRNA detection of gene selected 
using DDD and computational tools. 
 
Blood samples were prospectively collected from an additional cohort of gastrointestinal carcinoma 
patients (n = 11) and from age and sex matched non-carcinoma donors (n = 10). All the patients included 
were in the advanced stage, including eight colorectal cancer stage IV, one stage III rectal cancer before 
any treatment, and two pancreatic adenocarcinomas (stages II and IV). Blood were collected in 10 ml 
EDTA-containing tubes. To eliminate skin-plug contamination of the blood sample from initial 
venipuncture, the first several milliliters of blood were discarded. Samples were subjected to lysis and 
stabilized, in less than 1 h after blood withdrawal, in guanidinium-based RNA/DNA stabilization reagent 
for blood/bone marrow (Roche, Mannheim, Germany) at 10% (v/v) without cell and plasma separation. 
The mixtures were stored at −80 °C until mRNA extraction. Isolation reagent for blood and bone marrow 
(Roche, Mannheim, Germany) was used for mRNA extraction. 
 
The study was approved by the Institutional Review Board of the Ethic Committee of Clinical 
Investigation of Galicia (Spain) and written informed consent was obtained from all patients. 
2.4. RNA extraction and qRT-PCR 
Isolation of total RNA from cell cultures was performed using High Pure RNA Isolation Kit (Roche, 
Mannheim, Germany) following manufacturer's instructions. From each cell line at 70% confluence, 10
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cells were obtained for RNA isolation. Total RNA was treated with DNase I. 
 
RNA isolation from FFPE tissue cores of each specimen was performed with Optimum™ FFPE RNA 
Isolation Kit (Ambion, Diagnostics); manufacturer's protocol was followed. 
 
RNA isolated from human normal bone marrows were purchased from BD Biosciences-Clontech. 
Total RNA was derived from three different pools of normal human bone marrows (n = 23). 
 
mRNA isolation from blood samples was performed with mRNA Isolation Kit for Blood/Bone 
Marrow (Roche, Mannheim, Germany), following manufacturer's recommendations. Briefly, total nucleic 
acid fraction was adsorbed to magnetic glass particle and poly(A)+ RNA was captured by using biotin-
labeled oligo(dT) and streptavidin-coated magnetic particles. Each mRNA preparation was eluted in 12 μl 
RNase-free redistilled water. Purified poly (A)+ RNA was further processed in RT-PCR or stored at −80 
°C until use. RNA integrity was confirmed by 2% agarose gel electrophoresis and stained with ethidium 
bromide. 
2.5. cDNA synthesis 
Reverse-transcription (RT) was performed from total cellular and bone marrow RNA using 
SuperScript™ First-Strand Synthesis System for RT-PCR (Invitrogen™, USA) up to a total volume of 20 
μl × 1 μg of total RNA, 2.5 nM random hexamers, 0.5 mM dNTP mix, and 3 μl of DEPC-treated water 
were denatured at 65 °C for 5 min and chilled on ice for at least 1 min. On the other hand, 2 μl of 10× RT 
buffer, 5 mM MgCl2, 0.01 M DTT, and 40 U of RNaseOUT Recombinant Ribonuclease Inhibitor were 
mixed, collected by centrifugation, and incubated at 25 °C for 2 min. After incubation, 50 U of 
SuperScript™ RT) were added and incubated at 25 °C for 10 min, 42 °C for 50 min, and 70 °C for 15 min 
in a Thermocycler (Gene Amp PCR System 9700, Applied Biosystem). Finally, samples were chilled on 
ice and incubated with 2 U of RNAse H for 20 min at 37 °C before proceeding to amplification the target 
cDNA. For mRNA obtained from blood we follow the same procedure and 0.02 μg were subjected to 
cDNA synthesis. Positive and negative controls were included in each experiment. RNA extraction, 
reverse transcription-PCR assay setup, and post-reverse transcription-PCR product analysis were carried 
out in separate designated rooms to prevent cross-contamination. cDNA was quantified and assessed for 
purity using a GENIOUS UV spectrophotometer. cDNA concentration was measured at 260 nm. Also 
A260/A280 relation was calculated to know cDNA quality. 
2.6. Quantitative real-time reverse transcription-PCR analysis 
Real-time PCR analysis was performed, using primers and conditions shown in Table 1, on 
LightCycler
®
 480 Instrument (Roche, Mannheim, Germany) using LightCycler 480 SYBR Green I 
Master (Roche, Mannheim, Germany). PCR reaction consisted of 10 μl of Master Mix 2× conc., 0.35 μM 
of each forward and reverse primer, template cDNA and PCR-grade water up to a final volume of 20 μl in 
the LightCycler 480 Multiwell Plate 96. Multiwell Plate was centrifuged at 3000 rpm for 2 min and was 
loaded in the LightCycler 480 Instrument until the PCR program started. An initial activation at 95 °C for 
5 min was followed by an amplification target sequence 50 cycles of 95 °C for 10 s, 54–60 °C (depending 
on the primers pair used) for 10 s, and 72 °C (depending on the amplicon size amplified) were used. For 
melting curve analysis 1 cycle of 95 °C for 5 s, 70 °C for 15 s, and 95 °C for 1 s was used. Finally, a 
cooling step was used at 40 °C for 10 s. 
  
Table 1. qRT-PCR—primers and conditions: primers sequences, conditions and annealing temperature of real-time quantitative RT-
PCR used to amplify selected genes 
Primers Sequence Length (mer) %GC Annealing temperature (°C) 
     
PKP3 1R 5′-ggatgaaaggttccacagga-3′ 20 50 60 
PKP3 2F 5′-ggcccgcagccttcaggccgtgcc-3′ 24 79 
GNT-V 1F 5′-att ggc aag cca act ctg a-3′ 19 47 55 
GNT-V 1R 5′-ttg agg tca aca gtc cac aca-3′ 21 48 
AGR2 2F 5′-ctg gcc aga gat acc aca gtc-3′ 21 57 54 
AGR2 2R 5′-agt tgg tca ccc caa cct-3′ 19 58 
S100A16 2F 5′-tgg aga gga ggc aga ctg ag-3′ 20 60 54 
S100A16 2R 5′-cca cca gga caa tga ctg c-3′ 19 58 
LGALS4 1F 5′-aac ctt caa ccc gcc tgt-3′ 18 56 54 
LGALS4 1R 5′-gag ccc acc ttg aag ttg at-3′ 20 50 
LCN2 1F 5′-cag gac tcc acc tca gac ct-3′ 20 60 54 
LCN2 1R 5′-cac ata cca ctt ccc ctg ga-3′ 20 55 
MGC3047 1F 5′-cca gaa gtc ggg aaa gtc aa-3′ 20 50 54 
MGC3047 1R 5′-ctc act cct gta aag cat ctg g-3′ 22 50 
EFNB1 1F 5′-tca tga agg ttg ggc aag a-3′ 19 47 54 
EFNB1 1R 5′-gtg tgg cca tct tga cag tg-3′ 20 55 
ASS 1F 5′-aag ctt ggg gcc aaa aag-3′ 18 50 54 
ASS1R 5′-gta gcg gtc ctc ata cag tgc-3′ 21 57 
CLDN3 2F 5′-cca tta tcc ggg act tct aca ac-3′ 23 48 60 
CLDN3 2R 5′-gac acg agc agc aga gca-3′ 18 61 
EGFR 2F 5′-cag cca ccc ata tgt acc atc-3′ 21 52 60 
EGFR 2R 5′-aac ttt ggg cga cta tct gc-3′ 20 50 
S100A6 2F 5′-act gcg aca cag ccc atc-3′ 18 61 60 
S100A6 2R 5′-gaa gat ggc cac gag gag-3′ 18 61 
HPRT 1F 5′-tga cct tga ttt att ttg cat acc-3′ 24 33 60 
HPRT 1R 5′-cga gca aga cgt tca gtc ct-3′ 20 55 
     
 
We verified that amplifications and the expected size of each PCR product were specific. 1.8% 
agarose gel electrophoresis of all PCR products revealed a single band that corresponded to the single-
amplified products as predicted by the melting curve analysis of the PCR. The amplification efficiency 
was determined for both target and housekeeping genes and was equal (99–100%). 
 
PCR primers for mRNA amplification of the different selected genes were carefully designed using 
the web-based ProbeFinder software (Universal ProbeLibrary Design Center) [18] or via Roche Applied 
Science home page [19]. PCR primers have been positioned to span exon–intron boundaries, reducing the 
risk of detecting genomic DNA. Primers were purchased from Invitrogen™ (USA) and Roche 
(Mannheim, Germany). 
 
Suitable selection of housekeeping gene(s) was performed using Human Endogenous Control Gene 
Panel (TATAA Biocenter, Sweden). The Excel macro GeNorm VBA applet for Microsoft Excel was used 
to determine the gene(s) with most correlated expression in the set of samples. Homo sapiens HPRT 
(Hypoxanthine–guanine phosphoribosyltransferase) were used as internal control for blood, bone marrow, 
and cell-lines samples. Also housekeeping gene was used to verify integrity of RNA and efficacy of 
reverse transcription. Any specimen with inadequate HPRT mRNA was excluded from the study. 
  
Data analysis was performed with LigthCycler 480 Relative Quantification software (Roche, 
Mannheim, Germany). Relative levels of expression were calculated by the 2
−ΔΔCt
 method [20]. Each 
assay was done at least in triplicate and included marker-positive and marker-negative controls and 
reagent with no template controls. 
2.7. DNA sequencing 
At least one PCR product coming from each Real-time PCR experiment was used as template DNA. 
Products were purified by enzymatic method (ExoSAP-IT, Amersham USB). DNA sequencing was 
performed in a reference facility on ABI 3700 (Applied Biosystems) using Big Dye terminators. Forward 
and reverse primers used in sequencing reactions were the same as for the Real-time PCR, see Table 1. 
2.8. Statistical analysis 
Statistical significance of differences was evaluated at the 95% confidence level by non-parametric 
statistic, Mann–Whitney U-test; p-value <0.05 were considered to be significant. Receiver operating 
characteristics (ROC) curve analysis was used to evaluate the diagnostic discrimination power of the 
selected differentially expressed genes. The threshold value for optimal sensitivity and specificity of 
PKP3 and AGR2 mRNA relative expression levels (R.E.L.) was also determined by ROC analysis. All of 
the statistical analyses were performed using the SPSS 12.0 for Windows. 
3. Results 
3.1. Search for gastrointestinal tumor-associated biomarkers using computational tools 
Digital differential display (DDD) data were used to identify and prioritize molecular markers highly 
expressed in GI cancers but absent in blood and bone marrow-derived libraries. The pools used in this 
analysis, their ID libraries and the ESTs clustered are shown in Table 2. Differential over representation 
were found for 34 genes in colorectal cancer libraries, for 96 in gastric cancer libraries, and for 144 in 
pancreatic cancer libraries in comparison with hematopoietic libraries. Potential up-regulated targets of 
note from this study include, among others, genes involved in cell adhesion and cytoskeleton, cell 
signaling, growth factor activity, ribosomal proteins, calcium-related metabolism, heat shock proteins as 
well as hypothetical proteins. 
Table 2. Digital differential display: cDNA libraries: Pool of libraries, their identification numbers (IDs) and the expressed 
sequence tags (ESTs) clustered used in the digital differential display (DDD) bioinformatics tool 
Pool Lib (IDs) Clustered ESTs 
   
Colorectal cancer 842, 841, 840, 882, 1540, 988, 956, 987, 1447, 486 43918 
Gastric cancer 
10324, 10311, 10310, 10306, 10325, 10302, 10301, 10299, 10305, 14437, 1449, 
721, 733 
44581 
Pancreatic cancer 1460, 5551, 9885, 721, 733 42014 
Blood and bone marrow 7038, 7037, 6976, 6975, 8975, 11923, 931, 5948, 5566, 9724, 8613, 14381, 765 51208 
   
  
From this set, we specifically selected those ESTs whose expression was at least 10-fold higher in 
each set of cancer libraries and undetectable or low represented in hematopoietic control libraries, defined 
as an expression count equal or less than four in DDD output. After these filters, we obtained a collection 
of 30, 58, and 91 genes in colon, gastric and pancreatic cancer-derived cDNA libraries, respectively (Fig. 
1 and Table 3). 
 
 
 
Fig. 1. Overexpressed genes in colon, gastric and pancreatic cancer-derived cDNA libraries: Venn diagram showing overexpressed 
genes in colon, gastric and pancreatic cancer-derived cDNA libraries. Only those genes whose expression was at least 10-fold higher 
in each set of cancer libraries and undetectable or low represented in hematopoietic control libraries are shown. 
Table 3. Up-regulated genes in gastrointestinal tumors according to digital differential display (DDD) 
Gene name Gene Description UniGene # Function Folds 
EST 
counts in 
tumor 
libraries 
EST counts in 
hematopoietic 
libraries 
 
A: Colorectal 
 AGR2 
Anterior gradient 2 homolog (Xenopus 
laevis) 
Hs.226391 Secretory protein 14 42 3 
 ASS Argininosuccinate synthetase Hs.160786 Enzyme 24 24 0 
 
CEACAM5 
Carcinoembryonic antigen-related cell 
adhesión molecule 5 
Hs.220529 Receptor/surface/membrane 22 22 0 
 CLDN3 Claudin 3 Hs.25640 Receptor/surface/membrane 39 39 0 
 DIPA 
Hepatitis delta antigen-interacting 
protein A 
Hs.66713 Binding protein 20 20 0 
 EFNB1 Ephrin-B1 Hs.144700 Binding protein 20 20 0 
 FLNB 
Filamin B, beta (actin binding protein 
278) 
Hs.81008 Binding protein 26 26 1 
 GDF15 Growth differentiation factor 15 Hs.296638 Secretory protein 41 41 1 
 GMDS GDP-mannose 4,6-dehydratase Hs.105435 Enzyme 22 22 1 
 H1FX H1 histone family, member X Hs.75307 Binding protein 14 56 4 
 KLF5 Kruppel-like factor 5 (intestinal) Hs.84728 Binding protein 18 18 0 
 KRT18 Keratin 18 Hs.406013 Receptor/surface/membrane 42 126 3 
 KRT19 Keratin 19 Hs.309517 Receptor/surface/membrane 37 37 0 
 KRT8 Keratin 8 Hs.356123 Receptor/surface/membrane 78 78 1 
 LCN2 Lipocalin 2 (oncogene 24p3) Hs.204238 Secretory protein 19 19 0 
 LGALS4 
Lectin, galactoside-binding, soluble, 4 
(galectin 4) 
Hs.5302 Binding protein 30 30 0 
 
LOC374395 
Similar to RIKEN cDNA 1810059G22 Hs.381134 Hypothetical protein 21 21 0 
 
MGC3047 
Hypothetical protein Hs.76239 Hypothetical protein 25 25 1 
 MUC5B Mucin 5, subtype B, tracheobronchial Hs.103707 Secretory protein 24 24 0 
 PKP3 Plakophilin 3 Hs.148074 Receptor/surface/membrane 28 28 0 
 REG1A 
Regenerating islet-derived 1 alpha 
(pancreatic stone protein, pancreatic 
thread protein) 
Hs.49407 Secretory protein 27 27 1 
 REG4 
Regenerating islet-derived family, 
member 4 
Hs.105484 Secretory protein 25 25 1 
 RHOB Ras homolog gene family, member B Hs.406064 Enzyme 29 29 1 
 S100A16 S100 calcium binding protein A16 Hs.8182 Binding protein 23 23 0 
 S100A6 
S100 calcium binding protein A6 
(calcyclin) 
Hs.275243 Binding protein 10 39 4 
 SAFB Scaffold attachment factor B Hs.23978 Binding protein 18 18 0 
 SLC39A8 
Solote carrier family 39 (zinc 
transporter), member 8 
Hs.284205 Zinc transporter 14 28 2 
 
TACSTD1 
Tumor-associated calcium signal 
transducer 1 
Hs.692 Receptor/surface/membrane 19 19 0 
 WARP 
Von Willebrand factor A domain-
related protein 
Hs.449009 Secretory protein 22 22 0 
 ZFP36L2 Zinc finger protein 36, C3H type-like 2 Hs.78909 Binding protein 12 25 2 
B: Gastric 
 A2M Alpha-2-macroglobulin Hs.74561 Binding protein 37 37 1 
 AGR2 
Anterior gradient 2 homolog (Xenopus 
laevis) 
Hs.226391 Secretory protein 35 106 3 
 
ALDH1A1 
Aldehyde dehydrogenase 1 family, 
member A1 
Hs.76392 Enzyme 11 44 4 
 
ALDH3A1 
Aldehyde dehydrogenase 3 family, 
member A1 
Hs.575 Enzyme 45 45 0 
 ANKRD9 Ankyrin repeat domain 9 Hs.432945 Binding protein 43 43 0 
 ATP1B1 
ATPase, Na+/K+ transporting, beta 1 
polypeptide 
Hs.78629 Enzyme 25 25 0 
 CLDN4 Claudin 4 Hs.5372 Receptor/surface/membrane 27 27 1 
 CPA1 Carboxypeptidase A1 (pancreatic) Hs.2879 Enzyme 53 53 0 
 CPB1 Carboxypeptidase B1 (tissue) Hs.437028 Enzyme 20 20 0 
 
CREB3L1 
cAMP responsive element binding 
protein 3-like 1 
Hs.405961 Biniding protein 22 22 0 
 CTRB1 Chymotrypsinogen B1 Hs.449833 Enzyme 29 29 0 
 DDX41 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 41 
Hs.274317 Binding protein 14 59 4 
 DECR2 
2,4-Dienoyl CoA reductase 2, 
peroxisomal 
Hs.15898 Enzyme 19 19 0 
 ELA3A Enastase 3A, pancreatic (protease E) Hs.471034 Enzyme 27 27 0 
 
GLTSCR2 
Glioma tumor suppressor candidate 
region gene 2 
Hs.421907 Unknown function 11 47 4 
 GPX2 
Glutathione peroxidase 2 
(gastrointestinal) 
Hs.2704 Enzyme 21 21 0 
 GRN Granulin Hs.180577 Binding protein 29 29 1 
 ID1 
Inhibitor of DNA binding 1, dominant 
negative helix-loop-helix protein 
Hs.410900 Binding protein 19 19 0 
 JARID1C 
Jumonji, AT-rich interactive domain 1C 
(RBP2-like) 
Hs.103381 Binding protein 27 27 1 
 KLF13 Kruppel-like factor 13 Hs.7104 Binding protein 18 18 0 
 
KREMEN2 
Kringle containing transmembrane 
protein 2 
Hs.351474 Receptor/surface/membrane 25 25 0 
 KRT18 Keratin 18 Hs.406013 Receptor/surface/membrane 10 32 3 
 KRT19 Keratin 19 Hs.309517 Receptor/surface/membrane 21 21 0 
 KRT8 Keratin 8 Hs.356123 Receptor/surface/membrane 146 146 1 
 LDHA Lactate dehydrogenase A Hs.2795 Enzyme 17 383 22 
 LGALS4 
Lectin, galactoside-binding, soluble, 4 
(galectin 4) 
Hs.5302 Binding protein 19 19 0 
 LISCH7 
Liver-specific bHLH-Zip transcription 
factor 
Hs.312129 Binding protein 22 22 1 
 LRFN4 
Leucine-rich repeat and fibronectin type 
III domain containing 4 
Hs.148438 Binding protein 43 43 1 
 LYZ Lysozyme (renal amyloidosis) Hs.234734 Enzyme 16 32 2 
 MEIS3 
Meis 1, myeloid ecotropic viral 
integration site 1 homolog 3 (Mouse) 
Hs.380923 Binding protein 19 19 0 
 MUC1 Mucin 1, transmembrane Hs.89603 Secretory protein 26 26 0 
 MYEOV Myeloma overexpressed gene Hs.436000 Unknown function 21 21 0 
 MYH11 
Myosin, heavy polypeptide 11, smooth 
muscle 
Hs.78344 Binding protein 31 31 0 
 NQO1 
NAD(P)H dehydrogenase, quinone 1 
(NQO1) 
Hs.406515 Enzyme 10 42 4 
 P4HB 
Procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase) 
Hs.410578 Binding protein 14 56 4 
 PGA5 Pepsinogen 5, group I Hs.432854 Enzyme 122 122 1 
 PGC Progastricsin (pepsinogen C) Hs.1867 Enzyme 95 95 0 
 PLK2 Polo-like kinase2 (Drosophila) Hs.398157 Enzyme 29 29 1 
 PME-1 Protein phsphatase methylesterase-1 Hs.63304 Enzyme 15 30 2 
 PNLIP Pancreatic lipase Hs.102876 Enzyme 20 20 0 
 PRSS2 Protease, serine, 2 (trypsine 2) Hs.511525 Enzyme 91 91 1 
 PYCR1 Pyrroline-5-carboxylate reductase 1 Hs.458332 Enzyme 11 71 6 
 REG1A 
Regenerating islet-derived 1 alpha 
(pancreatic stone protein, pancreatic 
thread protein) 
Hs.49407 Secretory protein 55 55 1 
 REG1B 
Regenerating islet-derived 1 beta 
(pancreatic stone protein, pancreatic 
thread protein) 
Hs.4158 Secretory protein 23 23 0 
 REG4 
Regenerating islet-derived family, 
member 4 
Hs.105484 Secretory protein 68 68 1 
 RGS5 Regulator of G-protein signalling 5 Hs.24950 Binding protein 30 30 0 
 S100A6 
S100 calcium binding protein A6 
(calcyclin) 
Hs.275243 Binding protein 11 44 4 
 SDC1 Syndecan 1 Hs.82109 Binding protein 13 27 2 
 
SERPINB6 
Serine (or cysteine)proteinase inhibitor, 
clade B (ovalbumin), member 6 
Hs. 41072 Enzyme 13 27 2 
 SKB1 SKB1 homolog (S. pombe) Hs.367854 Binding protein 18 18 0 
 
SPARCL1 
SPARC-like 1 (mast9, Kevin) Hs.75445 Secretory protein 20 20 0 
 
TACSTD1 
Tumor-associated calcium signal 
transducer 1 
Hs.692 Receptor/surface/membrane 29 29 0 
 TGFB1I4 
Transforming growth factor beta 1-
induced transcript 4 
Hs.114360 Secretory protein 23 23 1 
 THBS3 Thrombospondin 3 Hs.169875 Binding protein 20 20 0 
 TM4SF3 
Transmembrane 4 superfamily member 
3 
Hs.84072 Receptor/surface/membrane 16 32 2 
 TRY2 Trypsin II precursor Hs.367767 Enzyme 24 24 0 
 
WBSCR21 
Williams Beuren síndrome chromosome 
region 21 
Hs.182476 Binding protein 20 20 0 
 ZNF499 Zinc finger protein 499 Hs.445346 Binding protein 45 45 0 
C: Pancreatic 
 ABCD1 
ATP-binding cassette, sub-family D 
(ALD), member 1 
Hs.159546 Binding protein 34 34 1 
 ADAM15 
A disintegrin and metalloproteinase 
domain 15 (metargidin) 
Hs.312098 Enzyme 31 31 1 
 AGR2 
Anterior gradient 2 homolog (Xenopus 
laevis) 
Hs.226391 Secretory protein 42 127 3 
 AHSA1 
AHA1, activator of heat shock 90 kDa 
protein ATPase homolog 1 (yeast) 
Hs.204041 Enzyme 23 23 1 
 
ALDH3A1 
Aldehyde dehydrogenase 3 family, 
member A1 
Hs.575 Enzyme 85 85 0 
 APG4D 
APG4D autophagy 4 homolog D (S. 
cerevisiae) 
Hs.512799 Enzyme 52 52 0 
 ATAD3A 
ATPase family, AAA domain 
containing 3A 
Hs.467479 Enzyme 21 21 0 
 ATP1B1 
ATPase, Na+/K+ transporting, beta 1 
polypeptide 
Hs.78629 Enzyme 23 23 0 
 C1S 
Complement component 1, s 
subcomponent 
Hs.458355 Enzyme 23 23 1 
 CAPN1 Calpain 1 (mu/I) large subunit Hs.356181 Enzyme 31 31 1 
 CCT7 
Chaperonin containing TCP1, subunit 7 
(eta) 
Hs.368149 Binding protein 22 89 4 
 
CDC42EP4 
CDC42 effector protein (Rho GTPase 
binding) 4 
Hs.3903 Binding protein 180 180 0 
 CLDN4 Claudin 4 Hs.5372 Receptor/surface/membrane 37 37 1 
 CPA1 Carboxypeptidase A1 (pancreatic) Hs.2879 Enzyme 55 55 0 
 CPB1 Carboxypeptidase B1 (tissue) Hs.437028 Enzyme 28 28 0 
 CRABP2 Cellular retinoic acid binding protein 2 Hs.183650 Binding protein 21 21 0 
 CTRB1 Chymotrypsinogen B1 Hs.74502 Enzyme 18 18 0 
 CTSD 
Cathepsin D (lysosomal aspartyl 
protease) 
Hs.34375 Enzyme 10 31 3 
 DHRSX 
Dehydrogenase/reductase (SDR family) 
X-linked 
Hs.11779 Enzyme 53 53 0 
 DKK3 Dickkopf homolog 3 (Xenopus laevis) Hs.130865 Secretory protein 99 99 0 
 DLGAP4 
Discs, large (Drosophila) homolog-
associated protein 4 
Hs.249600 Binding protein 18 36 2 
 DRAP1 
DR1-associated protein 1 (negative 
cofactor 2 α) 
Hs.356742 Binding protein 24 24 1 
 EEF1A2 
Eukaryotic translation elongation factor 
1 alpha 2 
Hs.433839 Binding protein 59 59 0 
 EGLN2 Egl nine homolog 2 (C. elegans) Hs.324277 Binding protein 29 29 0 
 EIF4G1 
Eukaryotic translation initiation factor 4 
gamma, 1 
Hs.433750 Binding protein 13 26 2 
 ELA3A Enastase 3A, pancreatic (protease E) Hs.471034 Enzyme 33 33 0 
 ELF3 
E74-like factor 3 (ets domain 
transcription factor, ephitelial specific) 
Hs.67928 Binding protein 20 20 1 
 EPHA2 EphA2 Hs.171596 Receptor/surface/membrane 19 19 0 
 FKBP4 FK506 binding protein 4, 59 kDa Hs.848 Binding protein 31 63 2 
 FLJ23322 Hypothetical protein Hs.387601 Hypothetical protein 58 58 1 
 FLNB 
Filamin B, beta (actin binding protein 
278) 
Hs.81008 Binding protein 30 30 1 
 FLNC 
Filamin C, gamma (actin binding 
protein 280) 
Hs.58414 Binding protein 67 67 0 
 GCG Glucagon Hs.423901 Enzyme 74 74 0 
 GSN Gelsolin (amyloidosis, Finnish type) Hs.446537 Binding protein 10 30 3 
 HAS3 Hyaluronan synthase 3 Hs.85962 Enzyme 23 23 1 
 HMGA1 High mobility group AT-hook 1 Hs.57301 Binding protein 21 108 5 
 IDS Iduronate 2-sulfatase (Hunter syndrome) Hs.303154 Enzyme 21 21 0 
 IFI27 Interferon, alpha-inducible protein 27 Hs.278613 Receptor/surface/membrane 25 25 1 
 IGFBP6 
Insulin-like growth factor binding 
protein 6 
Hs.274313 Binding protein 22 22 0 
 ITGB4 Integrin, beta 4 Hs.85266 Cell adhesion molecules 19 19 0 
 ITGB6 Integrin, beta 6 Hs.57664 Cell adhesion molecules 23 23 0 
 JUP Junction plakoglobin Hs.2340 Cell adhesion molecules 57 57 1 
 KRT13 Keratin 13 Hs.433871 Receptor/surface/membrane 28 28 0 
 KRT17 Keratin 17 Hs.2785 Receptor/surface/membrane 37 112 3 
 KRT18 Keratin 18 Hs.406013 Receptor/surface/membrane 116 349 3 
 KRT19 Keratin 19 Hs.309517 Receptor/surface/membrane 163 163 0 
 KRT5 Keratin 5 Hs.433845 Receptor/surface/membrane 79 79 0 
 KRT6A Keratin 6A Hs.367762 Receptor/surface/membrane 37 37 0 
 KRT7 Keratin 7 Hs.23881 Receptor/surface/membrane 39 79 2 
 KRT8 Keratin 8 Hs.356123 Receptor/surface/membrane 223 223 1 
 KRTHB1 Keratin, hair, Basic, 1 Hs.170925 Receptor/surface/membrane 34 34 1 
 LAMC2 Laminin, gamma 2 Hs.54451 Cell adhesion molecule 27 27 0 
 LCN2 Lipocalin 2 (encogen 24p3) Hs.204238 Secretory protein 55 55 0 
 
LOC142678 
Skeletrophin Hs.135805 Binding protein 41 41 1 
 LRP1 
Low density lipoprotein-related protein 
1(alpha-2-macroglobulin receptor) 
Hs.162757 Receptor/surface/membrane 13 27 2 
 LUM Lumican Hs.406475 Binding protein 10 63 6 
 LY6E Lymphocyte antigen 6 complex, locus E Hs.77667 Receptor/surface/membrane 21 42 2 
 MGAT4B 
Mannosyl (alpha-1,3)-glycoprotein beta-
1,4-N-acetylglucosaminyltransferase, 
isoenzyme B 
Hs.437277 Enzyme 69 69 0 
 
MGC10471 
Hypothetical protein Hs.24998 Hypothetical protein 109 109 1 
 
MGC2776 
Hypothetical protein Hs.335550 Hypothetical protein 49 49 0 
 MGLL Monoglyceride lipase Hs.409826 Enzyme 21 21 1 
 MRPL49 Mitochondrial ribosomal protein L-49 Hs.75859 Ribosomal protein 11 59 5 
 MRPS12 Mitochondrial ribosomal protein S12 Hs.411125 Ribosomal protein 23 23 0 
 MUC5B Mucin 5, subtype B, tracheobronchial Hs.103707 Secretory protein 34 34 0 
 NID Nidogen (enactin) Hs.356624 Binding protein 82 82 1 
 NRBP Nuclear receptor binding protein Hs.272736 Binding protein 16 50 3 
 NUMBL Numb homolog (Drosophila)-like Hs.326953 Unknown function 20 20 0 
 P4HB 
Procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase) 
Hs.410578 Enzyme 14 57 4 
 PAK4 p21 (CDKN!A)-activated kinase 4 Hs.20447 Binding protein 26 26 0 
 PCBD 
6-Pyruvoyl-tetrahydropterin 
synthase/dimerization cofactor of 
hepatocyte nuclear factor 1 alpha 
(TCF1) 
Hs.3192 Enzyme 33 33 1 
 PCQAP 
PC2 (positive cofactor 2, multiprotein 
complex) glutamina/Q-rich-associated 
protein 
Hs.410347 Transcription regulatory 
protein 
21 43 2 
 PKP3 Plakophilin 3 Hs.148074 Receptor/surface/membrane 23 23 0 
 PLAT Plasminogen activator, tissue Hs.274404 Enzyme 32 32 1 
 PLEC1 
Plactin 1, intermediate filament binding 
protein 500 kDa 
Hs.79706 Binding protein 40 40 1 
 PNLIP Pancreatic lipase Hs.102876 Enzyme 24 24 0 
 PRSS2 Protease, serine, 2 (trypsin 2) Hs.511525 Enzyme 94 94 1 
 PRSS3 Protease, serine, 3 (mesotrypsin) Hs.435699 Enzyme 31 31 1 
 RAC1 
Ras-related C3 botulinum toxin 
substrate 1 (rho family, small GTP 
binding protein Rac1) 
Hs.413812 Binding protein 18 73 4 
 REG1A 
Regenerating islet-derived 1 alpha 
(pancreatic stone protein, pancreatic 
thread protein) 
Hs.49407 Secretory protein 46 46 1 
 REG1B 
Regenerating islet-derived 1 beta 
(pancreatic stone protein, pancreatic 
thread protein) 
Hs.4158 Secretory protein 24 24 0 
 
RGS19IP1 
Regulador of G-protein signalling 19 
interacting protein 1 
Hs.6454 Receptor/surface/membrane 12 24 2 
 SCD 
Stearoyl-CoA desaturase (delta-9-
desaturase) 
Hs.119597 Enzyme 29 59 2 
 SCNN1A 
Sodium channel, nonvoltage-gated 1 
alpha 
Hs.446415 Binding protein 22 22 0 
 SDC1 Syndecan 1 Hs.82109 Receptor/surface/membrane 12 24 2 
 
SERPINA1 
Serine (or cysteine) proteinase inhibitor, 
clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
Hs.297681 Enzyme 26 26 0 
 SFRP2 Secreted frizzled-related protein 2 Hs.31386 Secretory protein 29 29 0 
 SSFA2 Sperm specific antigen 2 Hs.438599 Receptor/surface/membrane 41 41 0 
 STMN3 Stathmin-like 3 Hs.285753 Binding protein 12 63 5 
 SUGT1 
SGT1, supressor of G2 allele of SKP1 
(S. cerevisiae) 
Hs.107776 Binding protein 24 24 1 
 TIMM50 
Translocase of inner mitochondrial 
membran 50 homolog (yeast) 
Hs.355819 Enzyme 17 51 3 
 TMEPAI 
Transmembrane, prostate androgen-
induced RNA 
Hs.83883 Unknown function 20 40 2 
       
 
Hits (known ESTs) showing ≥10-fold differences in the tumor-derived libraries in comparison with normal blood and bone marrow 
tissue-derived cDNA libraries are shown: colorectal (A), gastric (B) and pancreatic (C). Gene name, gene description, gene function 
and UniGene number of each hit are also shown. EST counts in tumors and hematopoietics libraries are shown. The last column of 
the tables indicates the number of fold differences in the gastrointestinal tumor-derived libraries in comparison with normal tissue-
derived cDNA libraries. When EST counts in hematopoietics libraries were zero, EST counts in tumors are considered as fold 
difference. 
Among all of the up-regulated genes obtained, we identified several known genes which have 
previously been shown to be overexpressed in gastrointestinal tumors, and proposed as micrometastasis 
markers [21] as keratins 8, 18, and 19, CEACAM5, and tumor-associated calcium signal transducer 1 
(TACSTD1). The tissue distribution and tumor specificity were analyzed using representation profiles 
obtained with virtual northern (Table 4). Based on in silico data we could predict that some of the markers 
could be expressed in the hematopoietic compartment. 
  
Table 4. Expression of selected markers in gastrointestinal cancers, bone marrow and white blood cells: EST and SAGE data 
 
Colon cancer  Gastric cancer  Pancreatic cancer  Bone marrow  Blood 
 EST Data SAGE data  EST data SAGE data  EST data SAGE data  EST data SAGE data  SAGE data 
              
PKP3 35/170084 27/643586  11/70532 74/448716  23/75487 13/189999  0/44611 0/282890  4/846268 
AGR2 90/151938 45/643586  117/65595 342/448716  133/74783 36/189999  3/44571 0/282890  0/846268 
LCN2 48/170084 53/643586  17/70532 165/448716  60/75487 213/189999  2/44611 90/282890  2/846268 
EFNB1 30/170084 21/643586  1/70532 28/448716  9/75487 7/189999  0/44611 2/282890  11/846268 
ASS1 62/170084 147/643586  17/70532 41/448716  20/75487 16/189999  0/44611 0/282890  3/846268 
LGALS4 93/170084 56/643586  18/70532 232/448716  8/75487 46/189999  0/44611 0/282890  1/846268 
MGC3047 1/170084 0/643586  2/70532 9/448716  6/75487 8/189999  0/44611 0/282890  0/846268 
CLDN3 152/170084 80/643586  6/70532 96/448716  1/75487 29/189999  0/44611 0/282890  7/846268 
S100A16 46/170084 164/643586  5/70532 73/448716  20/75487 66/189999  2/44611 0/282890  1/846268 
S100A6 65/151938 506/643586  49/65595 656/448716  68/74783 480/189999  3/44571 77/282890  625/846268 
GNT-V 4/151938 2/643586  1/65595 0/448716  0/74783 0/189999  0/44571 0/282890  0/846268 
EGFR 7/151938 1/643586  3/65595 2/448716  0/74783 0/189999  0/44571 0/282890  0/846268 
              
 
Each column represents the number of ESTs or SAGE tags corresponding to the gene divided by the total number of ESTs or SAGE 
tags in all libraries with the given tissue/histology. Only SAGE data are available for white cells blood. PKP3, plakophilin 3; AGR2, 
anterior gradient homolog 2; LCN2, lipocalin 2 (oncogene 24p3); EFNB1, ephrin-B1; ASS1, argininosuccinate synthetase; 
LGALS4; lectin, galactoside-binding, soluble, 4 (galectin 4); MGC3047, hypothetical protein, MXRA8; CLDN3, claudin 3; 
S100A16, S100 calcium binding protein A16; S100A6, S100 calcium binding protein A6 (calcyclin); GNT-V, beta-1,6-N-
acetylglucosaminyltransferase V, MGAT 5; EGFR, epidermal growth factor receptor. 
3.2. Experimental validation of the in silico data: qRT-PCR in cell lines 
Criteria to select molecular markers identified by bioinformatic approach for quantitative real-time 
PCR studies are described in “Section 2.1”. In brief, we select those novel markers with absent or low 
expression in blood and bone marrow-derived EST libraries and high expression in gastrointestinal 
cancer-derived EST libraries. In addition functional annotations based on Gene Ontology and related with 
epithelial cellular components or (potentially) with metastatic process [22] were taken into account. 
 
In this way, we chose PKP3, AGR2, LCN2, S100A16, S100A6, EFNB1, ASS1, LGALS4, 
MGC3047/MXRA8, and CLDN3 for further experimental validation. 
 
Interestingly PKP3, LGALS4, CLDN3, and EFNB1 were involved in cell adhesion, following 
biological process annotations in Gene Ontology. S100A6 and S100A16 are related in calcium-dependent 
protein binding. ASS1 has argininosuccinate synthase activity. No significantly overrepresented GO 
annotations were found for AGR2, LCN2 and MGC3047/MXRA8. 
 
The expression of these selected markers was compared against EGFR and GNT-V, both described as 
overexpressed in gastrointestinal cancer. The expression levels of these genes were measured in 10 
gastrointestinal tumor cell-lines (eight colorectal tumor cell-lines, one gastroesophageal cell-line, and one 
pancreatic cell-line). The values obtained were compared against three hematopoietic tumor cell-lines 
(Jurkat, K562, and KG1) and three different pools of normal bone marrow that include 23 individual 
samples. All selected genes assessed showed higher expression levels in gastrointestinal tumor cell-lines 
than in normal human bone marrow with two exceptions, LCN2 and MGC3047 (Fig. 2). LCN2 showed 
lower expression levels in all gastrointestinal tumor cell-lines tested than normal human bone marrow. 
MGC3047 only showed higher expression levels over to those obtained with normal human bone marrow 
in OJC1 pancreatic tumor cell-line. The rest of the markers showed high expression in at least 7–10 
gastrointestinal tumor cell-lines than in normal human bone marrow. Also, S100A16 was the unique 
marker assessed that showed higher expression levels than normal human bone marrow in all tumor cell-
lines tested. Although GNT-V was expressed in 8 out of 10 cell digestive cancer cell-lines, its values were 
together with LCN2, EFNB1, ASS1, and MGC3047, the ones that showed the lowest expression in the 
tumor cell-lines assessed and they were not selected for blood mRNA quantification. 
 
 
 
Fig. 2. Expression profile in cell-lines and normal human bone marrows: heat-map showing relative mRNA expression of in silico 
selected genes (rows) in cell-lines and bone marrow (columns). mRNA relative expression were measured by qRT-PCR. Results are 
the mean of at least three independent measurements. Data were normalized vs. the values obtained in human normal bone marrow. 
Relative expression levels are shown in a color scale. Genes are described in Table 3. Cell-lines (columns) are as shown: colorectal 
cancer (Gp5d, LoVo, DLD1, LS513, HT29, OJC4, OJC5, OJC6); gastric adenocarcinoma (OE19); pancreatic carcinoma (OJC1); 
hematopoietic (Jurkat, KG1 and K562); normal human bone marrows (BM). *Indicated those genes selected for their mRNA 
quantification in blood samples from patients. 
Among all the genes assessed, PKP3, AGR2, S100A16, S100A6, LGALS4, and CLDN3 showed the 
most highly expression values with regard to normal human bone marrow. 
3.3. mRNA quantitative detection of selected genes in peripheral blood from patients with gastrointestinal 
cancer and controls 
We chose PKP3, AGR2, S100A6, S100A16, LGALS4, and CLDN3 for mRNA quantitative detection 
in peripheral blood samples from gastrointestinal cancer patients and controls. All of them showed an 
expression up to 10
2
- to 10
5
-fold higher in tumor cell-lines than in normal human bone marrow. Also, 
EGFR mRNA expression was measured in blood samples in order to compare their results with those 
obtained with the mRNA markers selected. All of these were expressed in at least 8 out of 10 tumor cell-
lines. 
  
Among the six potential molecular markers assessed in-patient and matched control blood samples, 
PKP3 and AGR2 showed the most remarkable results (Table 5 and Fig. 3). Values for PKP3 and AGR2 
mRNA were significantly higher in blood samples from gastrointestinal cancer patients than in blood 
samples from non-carcinoma patients with a significant level of p = 0.000 and 0.019, respectively (Mann–
Whitney U-test). 
Table 5. Median relative expression levels and ratios of candidate mRNA markers of circulating tumor cells in patients and controls 
blood 
Gene name Gene symbol Patients blood Controls blood Patients: controls 
     
Plakophilin 3 PKP3 175.42 9.32 18.82 
Anterior gradient 2 AGR2 13.50 0 * 
Claudin 3 CLDN3 8040.27 29,299 2.74 
Galectin 4 LGALS4 27,073 13,070 2.07 
S100 calcium binding protein A6 (calcyclin) S100A6 53,840 58548.6 0.92 
S100 calcium binding protein A16 S100A16 41,945 23,090 1.82 
Epidermal growth factor receptor EGFR 67.22 24.64 2.72 
     
 
mRNA levels were measured by qRT-PCR as described in Section 2. Results are the mean of at least three independent 
measurements. *There was no AGR2 expression in normal bloods. 
 
 
 
Fig. 3. mRNA expression levels of PKP3, AGR2, LGALS4, CLDN3, S100A6, S100A16 and EGFR mRNA in peripheral blood: 
mRNA expression levels of PKP3, AGR2, LGALS4, CLDN3, S100A6, S100A16 and EGFR mRNA (Y-axis) determined in peripheral 
blood from non-carcinoma patients (C) and patients (P) with gastrointestinal cancer (X-axis). mRNA levels were measured by qRT-
PCR as described in Section 2. Results are the mean of at least three independent measurements. 
ROC curve analysis showed that the area under the ROC curve for PKP3 mRNA relative expression 
levels was 1.00 (S.E. = 0.00; p = 0.002). Optimal sensitivity (100%) and specificity (100%) was obtained 
by applying 56.61 as a PKP3 mRNA R.E.L. cutoff value. 
  
In the case of AGR2, ROC curve analysis showed that the area under the ROC curve for AGR2 
mRNA relative expression levels was 0.864 (S.E. = 0.092; 95% confidence range 0.683–1.045; p = 
0.023). Optimal sensitivity (72.7%) and specificity (100%) was obtained by applying 0.044 as AGR2 
mRNA R.E.L. cutoff value. In both cases, the calculated cutoff value may be useful to define positive or 
negative results and it discriminates samples of peripheral blood from patients with gastrointestinal cancer 
and control donors. 
 
Area under the ROC curve for EGFR mRNA relative expression levels was 0.564 (S.E. = 0.151; 95% 
confidence range 0.268–0.859; p = 0.692). Thus, in our series, EGFR mRNA amplification was not useful 
to differentiate between carcinoma patients and controls. In relation to the other four potential molecular 
markers assessed, S100A6, S100A16, LGALS4, and CLDN3, neither of them could be considered 
specific enough to detect circulating tumor cells. Perhaps increasing the number of samples analyzed and 
ROC curve analysis, or using logistic regression to determine a combination equation using all six 
molecular markers assessed could yield a stronger and powerful diagnostic discrimination test. 
 
PKP3 and AGR2 seem to be two new promising molecular markers for qRT-PCR detection of 
circulating tumor cells in peripheral blood samples from gastrointestinal cancer patients. Our findings had 
improved the previous results obtained with other common markers, widely used in micrometastasis 
detection, such as EGFR. 
3.4. mRNA detection of selected genes in colon cancer samples 
To validate the DDD data and the results obtained in cell-lines, we further investigated the mRNA 
expression of the genes PKP3, AGR2, LGALS4, and CLDN3 in colon cancer samples. These genes 
exhibited up-regulated expression based on both in silico data and GI cancer cell-lines qRT-PCR results. 
Absolute quantification by real-time RT-PCR analysis using RNA isolated from FFPE was used. Patient 
samples included primary colon tumors (n = 14). In addition metachronous metastatic lesions (hepatic 
and peritoneal) excised from two of these patients were studied. 
 
Among all of the markers tested, CLDN3 showed expression in a large number of tissues analyzed 
(90.9%) followed by AGR2 (81.8%), LGALS4 (45.4%), and PKP3 (40%). For PKP3, there was no 
concordant mRNA expression between primary and metastasis in the cases studied, suggesting a dynamic 
regulation of their expression during tumor progression. 
4. Discussion 
Metastatic hematogenous spreading is one of the most important factors affecting the prognosis of 
carcinoma patients, including gastrointestinal cancer. Detection of carcinoma cells in the blood or 
minimal deposits in distant organs as bone marrow could be important to identify patients at high risk of 
relapse or disease progression [7]. PCR amplification of tissue or tumor-selective mRNA is the most 
powerful tool for surrogate detection of this isolated tumor cells. However, specificity of different 
mRNA-based assays has been controversial and there is a need for a systematic evaluation for each new 
biomarker proposed. 
 
Our research aimed to identify, at first, a set of specific epithelial gene markers highly expressed in 
gastrointestinal cancer. Electronic databases analysis allowed us to obtain a list of genes that are 
differentially expressed, to the point of statistical significance, in colon, pancreas, and gastric libraries. 
We hypothesized that these transcripts could represent the molecular signature associated with CTC. 
Global gene expression profile of cancer cells isolated from blood has been recently described in colon, 
breast, and prostatic tumors, using an immunomagnetic enrichment and microarray analysis [23]. In a 
recent report, Solmi et al. [24] have used a microarray-based high-throughput screening method to 
identify candidate marker mRNAs for CTC detection. However, employing a conventional RT-PCR 
procedure they could not find a set of suitable and consistent mRNA marker for detection of colonic cells 
in the blood. In previous reports using both in silico data-mining tools and conventional RT-PCR, these 
authors [25] suggest that among 15 genes differentially expressed in colon, only non-SMC structural 
maintenance of chromosomes, element 1 protein (NSE1) and gastrin (GAS) mRNAs could be suitable for 
detection of circulating colon cancer cells in blood. 
 
To point out the validity of our results using an in silico approach, our set of overexpressed genes 
included different markers previously used for CTC detection. In addition, AGR2 and different S100 
proteins were identified in our work as well as in the CTC molecular profile proposed by Smirnov et al. 
[23]. 
 
To obtain independent evidence to support the bioinformatics-approach for selecting CTC markers, 
quantitative mRNA expression of selected genes were analyzed in gastrointestinal cell-lines, 
hematopoietic cell-lines, and normal bone marrows. In order to validate their usefulness as potential 
molecular markers for gastrointestinal disseminated tumor cell detection, these results were compared 
with those obtained for EGFR and GNT-V. 
 
Among all the genes assessed, PKP3, AGR2, S100A16, S100A6, LGALS4, and CLDN3 showed the 
most highly expressed values with regard to normal human bone marrow. For this reason they were 
chosen for further analysis for their expression in blood from gastrointestinal cancer patients and controls. 
One of the main problems with any mRNA-based assays is the illegitimate transcription of the so-called 
“epithelial specific transcripts” in hematopoietic compartment [[2], [3], [4]]. In our study, we included a 
quantitative RT-PCR approach and a significant number of controls samples (23 bone marrows and 10 
bloods) in order to select the most specific mRNA markers. 
 
In patient blood samples, qRT-PCR for PKP3 and AGR2 showed the most promising results. We 
could calculate an mRNA R.E.L. cutoff value of 56.61 and 0.044 for PKP3 and AGR2, respectively. 
These cut-off points may be useful to distinguish between samples of peripheral blood from 
gastrointestinal cancer patients and control samples. However, we need to underscore that all of the 
patients included in our series of blood samples were in advanced disease status. To better evaluate the 
predictive and prognostic role (if any) of PKP3 and AGR2 qRT-PCR assays in blood, a prospective study 
with a larger number, and less advanced, cancer patients are clearly needed. 
 
When we compared our results obtained for PKP3 and AGR2 with those obtained for EGFR, our 
findings suggest that PKP3 and AGR2 could be better for its use as surrogate markers for circulating 
tumor cells detection in patients with GI cancer. 
 
This is the first time that PKP3, a member of the p120ctn/plakophilin subfamily of armadillo proteins, 
is suggested as a molecular marker for CTC detection. PKP3 is present in desmosomes of epithelial cells 
and binds all three desmogleins, desmocollin, plakoglobin, desmoplakin, and the epithelial keratin 18. 
This protein not only functions in desmosome-dependent cell adhesion, but in signaling transduction 
[[26], [27], [28]]. 
 
In view of the importance of β-catenin and other armadillo proteins in tumor biology, it is surprising 
that up to now, knowledge about the occurrence of PKPs in tumors is limited and little is known about 
their possible biologic role in tumor invasion and metastasis [29]. Recent studies had shown evidences 
that PKP3 protein may serve as useful marker for predicting the clinical outcome of head and neck tumors 
[30] and non-small cell lung cancer [31]. Other investigators [32] had demonstrated that this protein is 
highly expressed in various types of adenocarcinomas (colorectal, pancreatic, and prostate). In our work, 
PKP3 mRNA was highly expressed in digestive cancer cell-lines (8/10) but less in colon cancer samples 
(40%). One limitation of our analysis was the use of RNA isolated from FFPE. Recently, we studied 
PKP3 protein by immunohistochemistry in a large set of digestive tumors and found its expression in 
66.7% of cases [33]. Aigner et al. have shown that PKP3 is repressed in the epithelial to mesenchymal 
transition of tumors under control by the E-cadherin repressor ZEB1 [34]. These data suggest, as 
previously stated [23] that gene expression signatures of CTCs may change as the disease progresses. In 
addition, selective suppression of gene transcription was one of the characteristics of the molecular 
signature associated with bone marrow micrometastasis in breast cancer [35]. 
 
In relation with AGR2, the human homolog of Xenopus anterior gradient 2 (XAG2), our results 
corroborated and complemented a previous study in which it has been postulated as a marker for 
detection of circulating tumor cells in peripheral blood of advanced cancer patients [23]. AGR2 mRNA is 
expressed in several normal human tissue types that are rich in epithelial cells, including colon, pancreas, 
lung, stomach, rectum, prostate, and breast [[36], [37], [38]]. AGR2 has been demonstrated to be up-
regulated not only in hormonal-dependent tumors as breast, endometrial, renal, and prostate cancers but 
also in lung carcinomas [39]. Using qRT-PCR analysis, we demonstrated an increased AGR2 expression 
in gastrointestinal cancer cell-lines and colon tumors. Although AGR2 function is not known, 
experimental data suggest that it could act as a survival factor through inhibition of p53, and enhancing 
tumor cell adhesion to substratum [[40], [41]]. 
 
However, identification of truly specific markers is a difficult task. Our quantitative RT-PCR assay 
demonstrated background expression in blood derived from non-tumor donors for S100A16, S100A6, 
LGALS4, and CLDN3. Although these gene transcripts were found highly expressed in cancer 
specimens, none of them could be considered specific enough, at first, for circulating epithelial cells 
detection. Their value in multigene qRT-PCR approach as a discrimination test could be analyzed using 
logistic regression and ROC curve. 
 
In conclusion, novel and known gastrointestinal-specific mRNA markers for circulating tumor cells 
have been identified through in silico analysis and validated in clinical material. Our results indicate that 
quantitative real-time reverse transcription-PCR assay targeted to PKP3 and AGR2 mRNAs might be 
helpful to detect circulating tumor cells in patients with gastrointestinal cancer. 
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